Jiangsu Aidea Pharmaceutical Co (SHSE:688488) ROCE % : -4.26% (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Jiangsu Aidea Pharmaceutical Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Jiangsu Aidea Pharmaceutical Co's annualized ROCE % for the quarter that ended in Mar. 2024 was -4.26%.

Jiangsu Aidea Pharmaceutical Co ROCE % Historical Data

The historical data trend for Jiangsu Aidea Pharmaceutical Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jiangsu Aidea Pharmaceutical Co ROCE % Chart

Jiangsu Aidea Pharmaceutical Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

7.80

5.15

-3.09

-10.39

-6.23

Jiangsu Aidea Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															0.71	-3.15	-7.31	-15.06	-4.26

Jiangsu Aidea Pharmaceutical Co ROCE % Calculation

Jiangsu Aidea Pharmaceutical Co's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-80.321	/	( ( (1655.549 - 331.675)	+	(1746.565 - 491.568) )	/ 2 )
	=	-80.321	/	( (1323.874	+	1254.997)	/ 2 )
	=	-80.321	/	1289.4355
	=	-6.23 %

Jiangsu Aidea Pharmaceutical Co's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-51.948	/	( ( (1746.565 - 491.568)	+	(1752.516 - 569.064) )	/ 2 )
	=	-51.948	/	( ( 1254.997	+	1183.452 )	/ 2 )
	=	-51.948	/	1219.2245
	=	-4.26 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Jiangsu Aidea Pharmaceutical Co (SHSE:688488) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Jiangsu Aidea Pharmaceutical Co ROCE % Related Terms

Thank you for viewing the detailed overview of Jiangsu Aidea Pharmaceutical Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Jiangsu Aidea Pharmaceutical Co (SHSE:688488) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jiangsu Aidea Pharmaceutical Co Ltd (SHSE:688488) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 2 Liuzhuang Road, Hanjiang District, Jiangsu Province, Yangzhou, CHN, 225008

Website

http://www.aidea.com.cn

Jiangsu Aidea Pharmaceutical Co Ltd produces and sells human-derived protein products, and also develops some generic drug businesses and distributes Abbott's HIV diagnostic equipment and reagents. The company focuses on development of new chemical entities of anti-tumor, anti-virus and cardiovascular areas, among which two NCE drugs for the treatment of Cancer and AIDS have been approved.

Executives

Yuan Yu	Core technical personnel
Fu He Liang	Director, core technical staff
Su Gu Fang	Core technical personnel
Zhang Ji Bing	Core technical personnel
Wang Jun	Directors, senior managers
Wang Guang Rong	Directors, senior managers
Yu Ke	Directors, senior managers

Jiangsu Aidea Pharmaceutical Co (SHSE:688488) Headlines

No Headlines